Neogenomics (NEO) Other Non-Current Liabilities (2017 - 2026)

Neogenomics (NEO) has reported Other Non-Current Liabilities for 10 consecutive years, with $12.0 million the latest figure, recorded in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $12.0 million, up 0.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (up 0.91% YoY), and the FY2025 annual result was $12.1 million, up 2.52% from the prior year.
• Other Non-Current Liabilities was $12.0 million for Q1 2026 at Neogenomics, roughly flat from $12.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $14.2 million in Q3 2022 and troughed at $11.5 million in Q2 2024.
• Average Other Non-Current Liabilities over 5 years is $12.7 million, with a median of $13.0 million recorded in 2024.
• Year-over-year, Other Non-Current Liabilities soared 281.47% in 2022 and fell 11.4% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $13.1 million in 2022, then declined by 0.16% to $13.0 million in 2023, then decreased by 9.68% to $11.8 million in 2024, then climbed by 2.52% to $12.1 million in 2025, then fell by 0.32% to $12.0 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $12.0 million in Q1 2026, $12.1 million in Q4 2025, and $12.0 million in Q3 2025.